Current Practice Trends and Treatment Guidelines for Reducing Hypercholesterolemia Risk
Considering the National Cholesterol Education Program’s guidelines for treating patients with hypercholesterolemia, managed care’s greatest challenge is the underdiagnosis and undertreatment of this condition. This supplement derives from a meeting of medical and legal experts who convened to discuss these and other issues faced by those who manage and treat patients with hypercholesterolemia. These concerns are discussed from the perspectives of practitioners, health plans, employers, and health economists.
- NCEP Guidelines for Treatment of Hypercholesterolemia
- Clinical and Economic Benefits of a Cardiovascular Risk-Reduction Program
- Employer Objectives Behind Value-Based Purchasing for Pharmacy Benefits
- A Pharmacoeconomic Approach to Managing Lipids
- Roundtable Discussion: Meeting the Challenges of Treating and Managing Hypercholesterolemia
Diabetes Intervention: Achieving Tight Glycemic Control Through Combination Therapy
The alarmingly rapid increase in prevalence of type 2 diabetes has profound implications for morbidity, mortality, and economic outcomes. Health plans that adopt aggressive approaches to treatment will reap substantial clinical and financial benefits. The articles in this supplement, which derive from the proceedings of the National Association of Managed Care Physicians Diabetes Advisory Board in November 2000, address issues relevant to these concepts.
- NCQA/HEDIS 2000 Guidelines for Diabetes
- A Retrospective Study of Persistence With Single-Pill Combination Therapy vs. Concurrent Two-Pill Therapy in Patients With Hypertension
- Glyburide/Metformin HCl Clinical Overview
- Blueprint for Conversion of Patients on Metformin and Sulfonylurea to Glucovance
New Options in the Treatment of Rheumatoid Arthritis
This supplement is based on a meeting of leading experts in rheumatology to discuss treatment options for rheumatoid arthritis. The goal of this meeting was to create a step-care algorithm for treatment. The presentations herein address advances in combination therapy that have resulted in a significant reduction in disease-related disability, measurable improvement in quality of life, and a substantial decrease in economic losses.
- Pharmaceutical Agents for the Treatment of Rheumatoid Arthritis
- Combination DMARD Therapy for Rheumatoid Arthritis
- Economic and Quality-of-Life Impact of Rheumatoid Arthritis
- Discussion/Development of RA Treatment Algorithm
New Evidence-Based Treatments for Depression
When depression is unrecognized and untreated, it can have negative consequences on medical resource utilization. Even when depression is treated, appropriate selection of pharmacologic therapy can make a difference in outcomes. This supplement, based on Magellan Behavioral Health’s 2001 Clinical Medical Retreat, addresses concepts in treatment and management of depression, including a discussion of drug-product selection based on differential efficacy and compelling considerations about antidepressant medication interactions.
- Depression’s Ripple Effect on Health Status and Costs
- Overview of Antidepressant Therapy
- Antidepressant Drug Interaction Considerations
- Using Pharmacoeconomic Data To Compare Antidepressant Therapies
- The Texas Medication Algorithm Project for Major Depression
- Cost-Effective Therapy: Translating Evidence Into Practice
Recent Advances in Care: Treatment of Acid-Related Disorders
The prevalence of acid-related disorders, which include duodenal ulcer disease, gastric ulcer disease, Zollinger-Ellison syndrome, and gastroesophageal reflux disease, is relatively high in the United States. This has a significant impact on quality of life and health care resource utilization. The articles in this supplement explore therapeutic approaches and best practices related to acid-related disorders.
- Health Care in the United States: Current and Future Challenges
- Impact of Acid-Related Disorders in the United States
- Comparative Pharmacology of Proton Pump Inhibitors
- Optimizing Acid-Suppression Therapy
- Evidence-Based Health Care: Making Health Policy and Management Decisions